Literature DB >> 1494965

Latent period for malignant mesothelioma of occupational origin.

B P Lanphear1, C R Buncher.   

Abstract

To estimate the minimal latent period for malignant mesothelioma of occupational origin, we reviewed 21 articles that documented latent periods for malignant mesothelioma, totaling 1690 cases. Of these, 1105 (65%) cases fulfilled the strict histologic and exposure criteria and were included in this analysis. Of these mesotheliomas, 99% had a latent period more than 15 years; 96% had a latent period of at least 20 years; and the observed probability of an occupational exposure within a decade of the first exposure was zero. The estimated median latent period was at least 32 years after the initial exposure. These epidemiologic conclusions are important in determining the source of a specific case of the disease, understanding the natural history of the disease, determining liability, and in aiding in the diagnosis of malignant mesotheliomas of occupational origin.

Entities:  

Mesh:

Year:  1992        PMID: 1494965

Source DB:  PubMed          Journal:  J Occup Med        ISSN: 0096-1736


  75 in total

1.  Malignant mesothelioma in south east England: clinicopathological experience of 272 cases.

Authors:  D H Yates; B Corrin; P N Stidolph; K Browne
Journal:  Thorax       Date:  1997-06       Impact factor: 9.139

2.  Malignant peritoneal mesothelioma in a pediatric patient mimicking inflammatory bowel disease.

Authors:  Cynthia Oberto; Kathleen B Schwarz; Elias Zambidis; Andrew B Campbell; Charles Paidas; Kenneth Lindyberg; Maria Oliva-Hemker
Journal:  Dig Dis Sci       Date:  2004-03       Impact factor: 3.199

3.  [Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma].

Authors:  A Scherpereel; P Astoul; P Baas; T Berghmans; H Clayson; P de Vuyst; H Dienemann; F Galateau-Salle; C Hennequin; G Hillerdal; C Le Pe'choux; L Mutti; J-C Pairon; R Stahel; P van Houtte; J van Meerbeeck; D Waller; W Weder
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2010-10

4.  BTS statement on malignant mesothelioma in the UK, 2007.

Authors: 
Journal:  Thorax       Date:  2007-11       Impact factor: 9.139

5.  Cytokine alteration and speculated immunological pathophysiology in silicosis and asbestos-related diseases.

Authors:  Shuko Murakami; Yasumitsu Nishimura; Megumi Maeda; Naoko Kumagai; Hiroaki Hayashi; Ying Chen; Masayasu Kusaka; Takumi Kishimoto; Takemi Otsuki
Journal:  Environ Health Prev Med       Date:  2009-03-18       Impact factor: 3.674

6.  Current issues in malignant pleural mesothelioma evaluation and management.

Authors:  Jing Ai; James P Stevenson
Journal:  Oncologist       Date:  2014-07-24

7.  Malignant vascular tumours of the pleura in "asbestos" workers and endothelial differentiation in malignant mesothelioma.

Authors:  R L Attanoos; S K Suvarna; E Rhead; M Stephens; T J Locke; M N Sheppard; F D Pooley; A R Gibbs
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

8.  An updated historical cohort mortality study of workers exposed to asbestos in a refitting shipyard, 1947-2007.

Authors:  Kimiko Tomioka; Yuji Natori; Shinji Kumagai; Norio Kurumatani
Journal:  Int Arch Occup Environ Health       Date:  2011-06-09       Impact factor: 3.015

Review 9.  The Cappadocia mesothelioma epidemic: its influence in Turkey and abroad.

Authors:  Salih A Emri
Journal:  Ann Transl Med       Date:  2017-06

10.  PTEN protein expression in malignant pleural mesothelioma.

Authors:  Vijay Agarwal; Anne Campbell; Kate L Beaumont; Lynn Cawkwell; Michael J Lind
Journal:  Tumour Biol       Date:  2012-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.